Skip to Content

'
Steven I. Sherman, M.D., F.A.C.E.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Naguib Samaan Distinguished Professor in Endocrinology, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Endocrine Multidisciplinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

1. Novel therapies for advanced or metastatic thyroid carcinoma

2. Optimal primary treatments for thyroid carcinoma

3. New approaches to monitoring patients with thyroid carcinoma

Clinical Interests

The Endocrine Multidisciplinary Center brings together experts who treat cancers and related diseases of the thyroid, parathyroid, pituitary and adrenal glands.   We also provide specialized care of genetic cancer syndromes, such as multiple endocrine neoplasia (MEN).  For general clinic information, please visit the Endocrine Center's website listed here:  Endocrine Center

For physician to physician referrals, please call our main office line at (713) 792-2841.

For new adult patient self referrals, please call our new patient referral coordinators at (713) 563-4400 or visit us at https://my.mdanderson.org/

International patients may complete this form International Center  or contact the International Center at 001-713-745-0450.  

 For general department information, please select the link below.

Department of Endocrine Neoplasia and Hormonal Disorders

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Department of Endocrine Neoplasia and Hormonal Disorders
Unit Number: 1461
Houston, TX 77030
Phone: 713-792-2841
Fax: 713-794-4065

Education & Training

Degree-Granting Education

1985 Johns Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1981 Harvard College, Cambridge, MA, AB, magna cum laude, Biochemistry and Molecular Biology

Postgraduate Training

7/1990-6/1991 Senior Clinical Fellowship, Endocrinology and Metabolism, Johns Hopkins Hospital, Baltimore, MD, Paul W. Ladenson, M.D.
7/1988-6/1990 Clinical Fellowship, Endocrinology and Metabolism, Johns Hopkins Hospital, Baltimore, MD, Paul W. Ladenson, M.D.
7/1986-6/1988 Clinical Residency, Medicine, Johns Hopkins Hospital, Baltimore, MD, John D. Stobo, M.D.
7/1985-6/1986 Clinical Internship, Medicine, Johns Hopkins Hospital, Baltimore, MD, John D. Stobo, M.D.

Board Certifications

1/2007 Endocrinology, Diabetes, and Metabolism
9/1988 Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Medical Director, Endocrine Multidisciplinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2006-9/2012

Other Appointments/Responsibilities

Chair, International Thyroid Oncology Group (ITOG), N/A, 5/2011-present
Director, National Thyroid Cancer Treatment Cooperative Study Group, Houston, TX, 1/1998-present

Honors and Awards

2010 Outstanding Clinical Publication in Thyroid, 7/2008-12/2009, American Thyroid Association
2007 International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism, The Endocrine Society and Pfizer Inc.
2002-present Named one of “Best Doctors” in United States

Selected Publications

Peer-Reviewed Original Research Articles

1. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In Papillary Thyroid Cancer, Preoperative Central Neck Ultrasound Detects Only Macroscopic Surgical Disease, But Negative Findings Predict Excellent Long-Term Regional Control and Survival. Thyroid 22(4):347-55, 4/2012. e-Pub 1/26/2012. PMID: 22280230.
2. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid 21(12):1309-16, 12/2011. PMID: 22136266.
3. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog 50(9):655-67, 9/2011. e-Pub 1/25/2011. PMCID: PMC3128656.
4. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19):2660-6, 7/1/2011. e-Pub 5/23/2011. PMID: 21606412.
5. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R, Busaidy NL. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 4/2011. e-Pub 2/2/2011. PMCID: PMC3070247.
6. Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 137(2):157-62, 2/2011. PMID: 21339402.
7. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)–refractory, differentiated thyroid cancer. BMC Cancer 11(1):349, http://www.biomedcentral.com/bmccancer, 2011. e-Pub 8/11/2011. PMCID: PMC3164634.
8. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95(11):5018-27, 11/2010. PMID: 20739388.
9. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw 8(11):1228-74, 11/2010. PMID: 21081783.
10. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck 32(7):829-36, 7/2010. PMID: 19885924.
11. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 6/15/2010. PMID: 20564403.
12. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 95(6):2588-95, 6/2010. PMID: 20392874.
13. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network. Medullary carcinoma. J Natl Compr Canc Netw 8(5):512-30, 5/2010. PMID: 20495082.
14. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits. Diabetes Care 33(2):428-433, 2/2010. PMCID: PMC2809297.
15. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 11/15/2009. e-Pub 11/10/2009. PMCID: PMC2784003.
16. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants either after recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94(11):4171-9, 11/2009. PMID: 19850694.
17. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 94(11):4423-32, 11/2009. e-Pub 10/9/2009. PMCID: PMC2775645.
18. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167-214, 11/2009. PMID: 19860577.
19. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19(10):1043-1048, 10/2009. PMID: 19772419.
20. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck 31(9):1152-63, 9/2009. e-Pub 4/2009. PMID: 19360746.
21. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794-801, 8/10/2009. e-Pub 6/29/2009. PMID: 19564535.
22. Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck 31(8):1031-8, 8/2009. PMID: 19360741.
23. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Post-operative external beam radiotherapy for differentiated thyroid cancer - Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74(4):1083-91, 7/15/2009. e-Pub 12/25/2008. PMCID: PMC2745400.
24. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 40(6):827-33, 6/2009. e-Pub 2/5/2009. PMID: 19200582.
25. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: USA case-control study. Hepatology 49(5):1563-70, 5/2009. PMID: 19399911.
26. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94(4):1310-6, 4/2009. e-Pub 1/21/2009. PMID: 19158200.
27. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 19(4):407-12, 4/2009. PMID: 19355831.
28. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3):419-23, 3/2009. PMID: 18798312.
29. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory (MDASI THY). Oncology 76(1):59-68, 2009. e-Pub 12/1/2008. PMID: 19052478.
30. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid 18(8):901-5, 8/2008. PMID: 18651821.
31. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359(1):31-42, 7/2008. PMID: 18596272.
32. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer-Local disease control in the modern era. Head Neck 30(7):883-888, 7/2008. PMID: 18213725.
33. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39(1):15-20, 1/2008. PMID: 17949783.
34. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/AKT and RAS/RAF-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93(1):278-84, 1/2008. PMID: 17989125.
35. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 11(6):1408-15, 11/2007. PMID: 18205710.
36. Sherman SI. Practice point commentary: Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma? Nat Clin Pract Endocrinol Metab 3(7):510-511, 7/2007. PMID: 17519916.
37. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM; National Comprehensive Cancer Network Thyroid Carcinoma Panel.. Thyroid carcinoma. J Natl Compr Canc Netw 5(6):568-621, 7/2007. PMID: 17623612.
38. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab 92(1):124-30, 1/2007. PMID: 17062760.
39. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q 22(3):231-8; discussion 239-40, 12/2006. PMID: 17146329.
40. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16(12):1229-42, 12/2006. PMID: 17199433.
41. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91(6):2201-2204, 6/2006. PMID: 16522694.
42. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 91(6):2205-8, 6/2006. PMID: 16595600.
43. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47(4):648-54, 4/2006. PMID: 16595499.
44. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91(3):878-84, 3/2006. PMID: 16394083.
45. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized controlled study. J Clin Endocrinol Metab 91(3):926-932, 3/2006. PMID: 16384850.
46. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237(3):794-800, 12/2005. PMID: 16304103.
47. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6):531-44, 6/2005. PMID: 16029119.
48. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Jr, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW. Thyroid carcinoma. J Natl Compr Canc Netw 3(3):404-57, 5/2005. PMID: 16002006.
49. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10(24):8594-602, 12/2004. PMID: 15623643.
50. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136(6):1183-91, 12/2004. PMID: 15657574.
51. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 8/2004. PMID: 15287039.
52. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525-34; discussion 534-5, 4/2004. PMID: 15051000.
53. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 186(6):702-9; discussion 709-10, 12/2003. PMID: 14672783.
54. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134(6):890-9; discussion 899-901, 12/2003. PMID: 14668720.
55. Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg 186(6):711-7, 12/2003. PMID: 14672784.
56. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monroe BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946-54; discussion 954-5, 12/2003. PMID: 14668727.
57. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg 19(6):479-81, 11/2003. PMID: 14625496.
58. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30(10):1371-7, 10/2003. PMID: 12856155.
59. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88(4):1433-41, 4/2003. PMID: 12679418.
60. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138(4):409-16; discussion 416, 4/2003. PMID: 12686527.
61. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma 3(4):249-52, 3/2003. PMID: 12672276.
62. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97(5):1186-94, 3/2003. PMID: 12599224.
63. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery 132(6):968-74; discussion 974-5, 12/2002. PMID: 12490843.
64. Ghori FY, Gutterman-Litofsky DR, Jamal A, Yeung SC, Arem R, Sherman SI. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid 12(11):1009-16, 11/2002. PMID: 12490079.
65. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 137(6):641-7, 6/2002. PMID: 12049533.
66. Wartofsky L, Sherman SI (group member). Management of low risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. the rhTSH-Stimulated Thyroglobulin Study Group. Thyroid. 12(7):583-590, 2002. PMID: 12193302.
67. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis. Surgery 130(6):921-30, 12/2001. PMID: 11742318.
68. McCutcheon IE, Kitagawa RH, Sherman SI, Bruner JM. Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report. Neurosurgery 48(5):1161-5; discussion 1165-6, 5/2001. PMID: 11334286.
69. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84(11):3877-85, 11/1999. PMID: 10566623.
70. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230(5):697-707, 11/1999. PMCID: PMC1420925.
71. Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L, Katz RL. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 87(3):155-60, 6/1999. PMID: 10385447.
72. Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr Pract 5(3):148-56, May-Jun, 5/1999. PMID: 15251688.
73. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340(14):1075-9, Jan-Feb, 4/1999. PMID: 10194237.
74. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 83(12):4195-203, 12/1998. PMID: 9851751.
75. Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, Abbruzzese JL. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 124(6):1115-22, 12/1998. PMID: 9854592.
76. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 129(8):622-7, 10/1998. PMID: 9786809.
77. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroid carcinoma treatment: Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012-21, 9/1998. PMID: 9731906.
78. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8(9):737-44, 9/1998. PMID: 9777742.
79. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 8(8):667-71, 8/1998. PMID: 9737361.
80. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11):3637-42, 11/1997. PMID: 9360519.
81. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 82(7):2153-8, 7/1997. PMID: 9215287.
82. Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med 101(2):192-8, 8/1996. PMID: 8757360.
83. Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine sodium. Am J Ther 2(10):814-818, 10/1995. PMID: 11854792.
84. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 96(6):531-5, 6/1994. PMID: 8017451.
85. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78(3):629-34, 3/1994. PMID: 8126134.
86. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 73(2):424-31, 1/1994. PMID: 8293410.
87. Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analogue with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 75(3):901-5, 9/1992. PMID: 1517383.
88. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A 89(12):5251-5, 6/1992. PMID: 1376915.
89. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 15(3):185-90, 3/1992. PMID: 1624678.
90. Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med 90(3):367-70, 3/1991. PMID: 2003519.

Invited Articles

1. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 96(7):2027-31, 7/2011. PMID: 21734003.
2. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol 24 Suppl 2:S44-52, 4/2011. PMID: 21455200.
3. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 80(5):592-601, 9/2010. PMID: 20471374.
4. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22(6):464-8, 8/2010. PMID: 20452757.
5. Sherman SI. Chemotherapy and immunotherapy for medullary thyroid carcinoma. UpToDate 18(2), 7/2010.
6. Sherman SI. Chemotherapy for differentiated thyroid cancer. UpToDate 18(2), 7/2010.
7. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: Patient selection, study design, and recent advances. Thyroid 19(12):1393-1400, 12/2009. PMID: 20001721.
8. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23(6):713-722, 12/2009. PMID: 19942148.
9. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 15(6):1-27, Sep-Oct, 9/2009. e-Pub 6/2009. PMID: 19546052.
10. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94(5):1493-9, 5/2009. e-Pub 3/2009. PMID: 19258410.
11. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 37(2):511-24, xi, 6/2008. PMID: 18502340.
12. Sherman SI. New approaches to therapy of thyroid malignancies. Clin Adv Hematol Oncol 5(7):539-541, 7/2007. PMID: 17679927.
13. Sherman SI. Cancer disparities and thyroid carcinoma. Curr Opin Endocrinol Metab 13:451-4, 2006.
14. Sherman SI. Review of undifferentiated thyroglobulin-positive thyroid cancer 45 years after treatment for papillary primary. Clin Adv Hemat Oncol 1(4):243, 2005.
15. Sherman SI. Commentary on: Angelos P. Current approaches to the treatment of well-differentiated thyroid cancer. Oncology (Huntington). 16(3):309-315, discussion 315, 318, 323-4,, 2002.
16. Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Moley JF, Evans DB. Thyroid cancer: 1999 update. Ann Surg Oncol 7(5):376-98, 6/2000. PMID: 10864346.
17. Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord 1(3)(3):165-71, 4/2000. PMID: 11705002.
18. Sherman SI. Thyroid carcinoma. Lancet 361(9356):501-11, 2000. PMID: 12583960.
19. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 16(1):12-5, Jan-Feb, 1/1999. PMID: 9890734.
20. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 16(1):30-3, Jan-Feb, 1999. PMID: 9890737.

Editorials

1. Sherman SI. Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. J Clin Endocrinol Metab 87(9):4059-4062, 2002. PMID: 12213844.
2. Sherman SI. Staging of thyroid carcinoma--reply. Cancer 83(5):848-50, 9/1998. PMID: 9731885.
3. Sherman SI. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med 13(1):60-1, 1998. PMID: 9462498.

Abstracts

1. Sherman SI, Michaelis CL, Gornet T, Fritsche HA, Waguespack SG, Hu MI, Busaidy NL, Jimenez C, Cabanillas ME, Cote GJ. EpCAM-Bearing Circulating Tumor Cells are Detectable in Patients with Metastatic Medullary but not Differentiated Thyroid Carcinoma, 10/2010.
2. Michaelis CL, Cote GJ, Santarpia L, Klein MJ, Gornet TG, Fritsche HA, Busaidy NL, Waguespack SG, Cabanillas ME, Hu MI, Jimenez C, Sherman SI. Detection of circulating tumor cells (CTCs) in patients with thyroid cancer. Endocr Rev 31(S1):S615, 6/2010.

Book Chapters

1. Hu M, Sherman SI. Endocrine Complications of Head and Neck Surgery. In: Complications in Head and Neck Surgery, 2nd Edition. Ed(s) DW Eisele, RV Smith. Mosby: Philadelphia, 85-103, 2009.
2. Sherman SI. Directions for Future Studies and Clinical Trials. In: Practical Management of Thyroid Cancer: A Multidisciplinary Approach. Ed(s) Mazzaferri EL, Harmer C,Mallick UJ, Kendall-Taylor P. Springer, 429-34, 2005.

Letters to the Editor

1. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI, from the National Thyroid Cancer Treatment Cooperative Study Group (NTCTCSG), Houston, Texas. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid 20(12):1423-4, 12/2010. PMID: 21054207.
2. Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid 17(3):283, 3/2007. PMID: 17381366.
3. Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med 103(3):249-50, 9/1997. PMID: 9316558.

Last updated: 7/18/2013